Aleglitazar

Aleglitazar

IUPAC name	(2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-benzothiophenyl]propanoic acid
Other names	Ro-0728804, R-1439
Identifiers
CAS number	[475479-34-6]
PubChem	10274777
SMILES	CC1=C(CCOc2ccc(C[C@H](OC)C(O[H])=O)c3c2C=CS3)N=C(c4ccccc4)O1
Properties
Molecular formula	C₂₄H₂₃NO₅S
Molar mass	437.50812
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references

Aleglitazar is a peroxisome proliferator-activated receptor agonist which is being developed by Hoffmann–La Roche for the treatment of type II diabetes. It is currently in phase II clinical trials.^[1]

[edit] References

^ ClinicalTrials.gov. A Study of Aleglitazar in Patients With Type 2 Diabetes. United States National Institutes of Health. Retrieved on 2008-03-19.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

v • d • e Oral antidiabetic drugs and Insulin analogs (A10)

Biguanides	Metformin

Sulfonylureas	Carbutamide, Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide

Alpha-glucosidase inhibitors	Acarbose, Miglitol, Voglibose

Thiazolidinediones (TZD)	Pioglitazone, Rivoglitazone^†, Rosiglitazone, Troglitazone^‡

Meglitinides	Nateglinide, Repaglinide, Mitiglinide

Dipeptidyl peptidase-4 (DPP-4) inhibitors	Alogliptin^†, Saxagliptin^†, Sitagliptin, Vildagliptin

Glucagon-like peptide-1 analog	Exenatide, Liraglutide^†, Albiglutide^†

Amylin analog	Pramlintide

Insulin analogs	fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir), Inhalable insulin (Exubera)

Dual PPAR agonists	Aleglitazar^†, Muraglitazar^§, Tesaglitazar^§

SGLT2 inhibitor	Dapagliflozin^†, Remogliflozin^†

^†Undergoing clinical trials. ^‡ Withdrawn from market. ^§Development halted.